IMRX
Immuneering Corporation
Price Chart
Latest Quote
$4.77
+0.17 (+3.70%)
Current Price
| Previous Close | $4.60 |
| Open | $4.68 |
| Day High | $4.80 |
| Day Low | $4.61 |
| Volume | 388,737 |
Stock Information
| Shares Outstanding | 64.70M |
| Total Debt | $3.73M |
| Cash Equivalents | $156.69M |
| Net Income | $-54.44M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $308.61M |
| EPS (TTM) | $-1.06 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $144.64M |
| Income | $-54.44M |
| Book/sh | $3.19 |
| Cash/sh | $2.42 |
| Employees | 55 |
Financial Ratios
| Quick Ratio | 31.50 |
| Current Ratio | 32.45 |
| Debt/Eq | 1.81 |
Returns & Margins
| ROA | -27.88% |
| ROE | -43.84% |
Ownership
| Insider Ownership | 13.48% |
| Institutional Ownership | 47.53% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.56 |
| P/B | 1.49 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $17.00 |
Technical Indicators
| SMA20 | $4.43 |
| SMA50 | $5.00 |
| SMA200 | $5.77 |
| RSI | 58.10 |
| ATR | 0.2769 |
| Shares Float | 49.44M |
| Short Float | 25.92% |
| Short Ratio | 8.75 |
| Volatility | 0.38 |
| Rel Volume | 0.20 |
Performance History
| Week | +8.16% |
| Month | -9.49% |
| Quarter | -10.34% |
| 6 Months | -19.29% |
| YTD | -27.95% |
| Year | +62.24% |
| 3 Years | -58.23% |
| 10 Years | -72.88% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $4.77 | 388,737 |
| 2026-06-24 | $4.60 | 1,299,700 |
| 2026-06-23 | $4.54 | 935,800 |
| 2026-06-22 | $4.44 | 1,070,700 |
| 2026-06-18 | $4.41 | 1,010,500 |
| 2026-06-17 | $4.41 | 1,879,900 |
| 2026-06-16 | $4.10 | 1,135,200 |
| 2026-06-15 | $4.19 | 900,400 |
| 2026-06-12 | $4.19 | 1,548,000 |
| 2026-06-11 | $4.12 | 2,191,600 |
| 2026-06-10 | $3.92 | 1,113,100 |
| 2026-06-09 | $4.03 | 1,382,500 |
| 2026-06-08 | $3.93 | 2,136,900 |
| 2026-06-05 | $4.27 | 1,441,600 |
| 2026-06-04 | $4.48 | 1,065,300 |
| 2026-06-03 | $4.55 | 1,942,200 |
| 2026-06-02 | $4.28 | 2,515,600 |
| 2026-06-01 | $4.49 | 8,965,100 |
| 2026-05-29 | $5.77 | 2,947,700 |
| 2026-05-28 | $5.06 | 2,718,500 |
| 2026-05-27 | $5.34 | 1,972,300 |
| 2026-05-26 | $5.27 | 2,082,700 |
About Immuneering Corporation
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Zacks âĸ 2026-06-12T13:48:00Z
IMRX Stock On Track For Worst Day In Nearly 5 Months â Whatâs Driving The Selloff?
Stocktwits âĸ 2026-06-01T19:58:01Z
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely
Simply Wall St. âĸ 2026-05-06T14:53:23Z
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears
MarketBeat âĸ 2026-04-14T07:02:25Z
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
24/7 Wall St. âĸ 2026-03-09T15:15:48Z
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3
MarketBeat âĸ 2026-02-28T07:07:14Z
Director of Immuneering Picks Up 1.8% More Stock
Simply Wall St. âĸ 2026-01-16T11:02:43Z
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition
Simply Wall St. âĸ 2026-01-11T15:09:40Z
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next
Simply Wall St. âĸ 2026-01-10T11:11:26Z
Immuneering Highlights 64% 12-Month Survival in Phase 2A Pancreatic Cancer Study, Eyes Phase 3
MarketBeat âĸ 2026-01-08T00:03:27Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $316,952 |
| Operating Revenue | $0 | $0 | $0 | $316,952 |
| Reconciled Cost Of Revenue | - | - | $0 | $158,122 |
| Cost Of Revenue | - | - | $0 | $158,122 |
| Expenses | ||||
| Total Expenses | $59,375,728 | $64,071,655 | $58,413,285 | $52,062,291 |
| Other Income Expense | $311,665 | $441,493 | $1,334,269 | $216,844 |
| Other Non Operating Income Expenses | $311,665 | $441,493 | $1,334,269 | $216,844 |
| Net Non Operating Interest Income Expense | $3,039,406 | $2,593,300 | $3,606,996 | $1,014,456 |
| Operating Expense | $59,375,728 | $64,071,655 | $58,413,285 | $51,904,169 |
| General And Administrative Expense | $17,298,000 | $16,078,000 | $16,760,000 | $15,607,000 |
| Rent Expense Supplemental | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-56,024,898 | $-61,036,608 | $-53,471,622 | $-50,513,568 |
| Net Interest Income | $3,039,406 | $2,593,300 | $3,606,996 | $1,014,456 |
| Interest Income | $3,039,406 | $2,593,300 | $3,606,996 | $1,014,456 |
| Normalized Income | $-56,024,898 | $-61,036,608 | $-53,471,622 | $-50,513,568 |
| Net Income From Continuing And Discontinued Operation | $-56,024,898 | $-61,036,608 | $-53,471,622 | $-50,513,568 |
| Total Operating Income As Reported | $-59,375,969 | $-64,071,401 | $-58,412,887 | $-51,744,868 |
| Net Income Common Stockholders | $-56,024,898 | $-61,036,608 | $-53,471,622 | $-50,513,568 |
| Net Income | $-56,024,898 | $-61,036,608 | $-53,471,622 | $-50,513,568 |
| Net Income Including Noncontrolling Interests | $-56,024,657 | $-61,036,862 | $-53,472,020 | $-50,514,039 |
| Net Income Continuous Operations | $-56,024,657 | $-61,036,862 | $-53,472,020 | $-50,514,039 |
| Pretax Income | $-56,024,657 | $-61,036,862 | $-53,472,020 | $-50,514,039 |
| Interest Income Non Operating | $3,039,406 | $2,593,300 | $3,606,996 | $1,014,456 |
| Operating Income | $-59,375,728 | $-64,071,655 | $-58,413,285 | $-51,745,339 |
| Depreciation Amortization Depletion Income Statement | $29,267 | $29,267 | $29,267 | $30,053 |
| Depreciation And Amortization In Income Statement | $29,267 | $29,267 | $29,267 | $30,053 |
| Amortization Of Intangibles Income Statement | $29,267 | $29,267 | $29,267 | $30,053 |
| Gross Profit | - | - | $0 | $158,830 |
| Per Share | ||||
| Diluted EPS | $-1.27 | $-2.04 | $-1.88 | $-1.91 |
| Basic EPS | $-1.27 | $-2.04 | $-1.88 | $-1.91 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-59,021,944 | $-63,686,581 | $-58,061,202 | $-51,468,087 |
| Reconciled Depreciation | $353,784 | $385,074 | $352,083 | $277,252 |
| EBITDA (Bullshit earnings) | $-59,021,944 | $-63,686,581 | $-58,061,202 | $-51,468,087 |
| EBIT | $-59,375,728 | $-64,071,655 | $-58,413,285 | $-51,745,339 |
| Diluted Average Shares | $44,011,830 | $29,981,565 | $28,416,558 | $26,386,864 |
| Basic Average Shares | $44,011,830 | $29,981,565 | $28,416,558 | $26,386,864 |
| Diluted NI Availto Com Stockholders | $-56,024,898 | $-61,036,608 | $-53,471,622 | $-50,513,568 |
| Amortization | $29,267 | $29,267 | $29,267 | $30,053 |
| Research And Development | $42,048,461 | $47,964,388 | $41,624,018 | $36,267,116 |
| Selling General And Administration | $17,298,000 | $16,078,000 | $16,760,000 | $15,607,000 |
| Other Gand A | $4,863,000 | $4,079,000 | $4,900,000 | $5,407,000 |
| Salaries And Wages | $12,435,000 | $11,999,000 | $11,860,000 | $10,200,000 |
| Tax Provision | - | - | - | $0 |
| Rent And Landing Fees | - | - | - | - |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $211,472,390 | $34,345,382 | $83,506,072 | $102,750,877 |
| Total Assets | $231,985,010 | $52,714,413 | $102,584,538 | $122,367,283 |
| Total Non Current Assets | $55,739,056 | $13,126,844 | $13,500,869 | $13,620,474 |
| Other Non Current Assets | $283,562 | $1,295,783 | $1,034,446 | $743,703 |
| Investmentin Financial Assets | $44,183,186 | $0 | - | $0 |
| Goodwill And Other Intangible Assets | $7,011,578 | $7,040,844 | $7,070,111 | $7,099,378 |
| Other Intangible Assets | $321,147 | $350,413 | $379,680 | $408,947 |
| Current Assets | $176,245,954 | $39,587,569 | $89,083,669 | $108,746,809 |
| Other Current Assets | $3,414,685 | $3,442,849 | $3,417,984 | $3,209,536 |
| Cash Cash Equivalents And Short Term Investments | $172,831,269 | $36,144,720 | $85,665,685 | $105,524,856 |
| Cash And Cash Equivalents | $128,645,025 | $36,144,720 | $59,405,817 | $72,636,886 |
| Receivables | - | - | $0 | $12,417 |
| Accounts Receivable | - | - | $0 | $12,417 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $3,824,425 | $4,162,857 | $4,462,959 | $4,841,682 |
| Long Term Debt And Capital Lease Obligation | $3,427,321 | $3,824,419 | $4,162,852 | $4,462,959 |
| Current Debt And Capital Lease Obligation | $397,104 | $338,438 | $300,107 | $378,723 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $13,501,042 | $11,328,187 | $12,008,355 | $12,517,028 |
| Total Non Current Liabilities Net Minority Interest | $3,427,321 | $3,824,419 | $4,162,852 | $4,462,959 |
| Current Liabilities | $10,073,721 | $7,503,768 | $7,845,503 | $8,054,069 |
| Other Current Liabilities | $291,513 | $233,665 | $259,770 | $19,796 |
| Payables And Accrued Expenses | $5,139,541 | $3,348,016 | $3,659,715 | $4,024,468 |
| Payables | $1,542,737 | $1,958,536 | $2,111,666 | $3,154,557 |
| Accounts Payable | $1,542,737 | $1,958,536 | $2,111,666 | $3,154,557 |
| Equity | ||||
| Common Stock Equity | $218,483,968 | $41,386,226 | $90,576,183 | $109,850,255 |
| Total Equity Gross Minority Interest | $218,483,968 | $41,386,226 | $90,576,183 | $109,850,255 |
| Stockholders Equity | $218,483,968 | $41,386,226 | $90,576,183 | $109,850,255 |
| Gains Losses Not Affecting Retained Earnings | $81,332 | $0 | $-778 | $-30,120 |
| Other Equity Adjustments | $81,332 | - | $-778 | $-30,120 |
| Retained Earnings | $-280,320,084 | $-224,295,186 | $-163,258,578 | $-109,786,956 |
| Preferred Securities Outside Stock Equity | - | - | - | $0 |
| Other | ||||
| Ordinary Shares Number | $64,648,230 | $31,050,448 | $29,271,629 | $26,418,732 |
| Share Issued | $64,648,230 | $31,050,448 | $29,271,629 | $26,418,732 |
| Tangible Book Value | $211,472,390 | $34,345,382 | $83,506,072 | $102,750,877 |
| Invested Capital | $218,483,968 | $41,386,226 | $90,576,183 | $109,850,255 |
| Working Capital | $166,172,233 | $32,083,801 | $81,238,166 | $100,692,740 |
| Capital Lease Obligations | $3,824,425 | $4,162,857 | $4,462,959 | $4,841,682 |
| Total Capitalization | $218,483,968 | $41,386,226 | $90,576,183 | $109,850,255 |
| Additional Paid In Capital | $498,658,072 | $265,650,362 | $253,806,267 | $219,640,912 |
| Capital Stock | $64,648 | $31,050 | $29,272 | $26,419 |
| Common Stock | $64,648 | $31,050 | $29,272 | $26,419 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $3,427,321 | $3,824,419 | $4,162,852 | $4,462,959 |
| Current Capital Lease Obligation | $397,104 | $338,438 | $300,107 | $378,723 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,245,563 | $3,583,649 | $3,625,911 | $3,631,082 |
| Current Accrued Expenses | $3,596,804 | $1,389,480 | $1,548,049 | $869,911 |
| Investments And Advances | $44,183,186 | $0 | - | $0 |
| Available For Sale Securities | $44,183,186 | - | - | - |
| Goodwill | $6,690,431 | $6,690,431 | $6,690,431 | $6,690,431 |
| Net PPE | $4,260,730 | $4,790,217 | $5,396,312 | $5,777,393 |
| Accumulated Depreciation | $-1,402,575 | $-1,081,715 | $-728,293 | $-418,337 |
| Gross PPE | $5,663,305 | $5,871,932 | $6,124,605 | $6,195,730 |
| Leases | $298,941 | $298,941 | $298,941 | $288,908 |
| Construction In Progress | $37,500 | $0 | - | - |
| Other Properties | $4,631,319 | $4,903,585 | $5,176,175 | $5,378,159 |
| Machinery Furniture Equipment | $695,545 | $669,406 | $649,489 | $528,663 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $44,186,244 | $0 | $26,259,868 | $32,887,970 |
| Treasury Shares Number | - | - | $0 | - |
| Other Investments | - | - | - | $0 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-45,486,821 | $-55,084,446 | $-49,311,380 | $-44,843,748 |
| Operating Activities | ||||
| Operating Cash Flow | $-45,344,595 | $-54,999,571 | $-48,968,634 | $-44,101,265 |
| Cash Flow From Continuing Operating Activities | $-45,344,595 | $-54,999,571 | $-48,968,634 | $-44,101,265 |
| Operating Gains Losses | $2,093 | $6,784 | $3,939 | $5,170 |
| Investing Activities | ||||
| Capital Expenditure | $-142,226 | $-84,875 | $-342,746 | $-742,483 |
| Investing Cash Flow | $-88,738,247 | $26,434,955 | $7,296,492 | $41,831,002 |
| Cash Flow From Continuing Investing Activities | $-88,738,247 | $26,434,955 | $7,296,492 | $41,831,002 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $229,518,971 | $4,237,397 | $28,200,003 | $0 |
| Financing Cash Flow | $226,583,147 | $5,303,519 | $28,441,073 | $19,004 |
| Cash Flow From Continuing Financing Activities | $226,583,147 | $5,303,519 | $28,441,073 | $19,004 |
| Net Other Financing Charges | $-3,726,266 | $-40,988 | $-203,768 | $-281,375 |
| Net Common Stock Issuance | $229,518,971 | $4,237,397 | $28,200,003 | $0 |
| Common Stock Issuance | $229,518,971 | $4,237,397 | $28,200,003 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $128,645,025 | $36,144,720 | $59,405,817 | $72,636,886 |
| Beginning Cash Position | $36,144,720 | $59,405,817 | $72,636,886 | $74,888,145 |
| Changes In Cash | $92,500,305 | $-23,261,097 | $-13,231,069 | $-2,251,259 |
| Proceeds From Stock Option Exercised | $790,442 | $1,107,110 | $444,838 | $300,379 |
| Net Investment Purchase And Sale | $-88,596,021 | $26,519,830 | $7,639,238 | $42,573,485 |
| Sale Of Investment | $0 | $31,930,000 | $52,300,000 | $92,678,000 |
| Purchase Of Investment | $-88,596,021 | $-5,410,170 | $-44,660,762 | $-50,104,515 |
| Net PPE Purchase And Sale | $-142,226 | $-84,875 | $-342,746 | $-742,483 |
| Purchase Of PPE | $-142,226 | $-84,875 | $-342,746 | $-742,483 |
| Change In Working Capital | $3,823,936 | $-925,383 | $-974,641 | $1,717,276 |
| Change In Other Current Liabilities | $-280,584 | $-326,207 | $-138,749 | $-106,586 |
| Change In Other Current Assets | $1,114,245 | $-261,337 | $-290,742 | $-360,200 |
| Change In Payables And Accrued Expense | $2,498,438 | $-312,974 | $-384,907 | $2,234,785 |
| Change In Accrued Expense | $2,899,237 | $-200,831 | $721,989 | $474,568 |
| Change In Payable | $-400,799 | $-112,143 | $-1,106,896 | $1,760,217 |
| Change In Account Payable | $-400,799 | $-112,143 | $-1,106,896 | $1,760,217 |
| Change In Prepaid Assets | $491,837 | $-24,865 | $-172,660 | $-284,346 |
| Stock Based Compensation | $6,311,135 | $6,501,366 | $5,727,135 | $4,064,446 |
| Asset Impairment Charge | $345,103 | $328,377 | $412,055 | $519,541 |
| Amortization Of Securities | $-155,748 | $-259,181 | $-1,017,583 | $-171,382 |
| Depreciation Amortization Depletion | $353,784 | $385,074 | $352,083 | $277,252 |
| Depreciation And Amortization | $353,784 | $385,074 | $352,083 | $277,252 |
| Amortization Cash Flow | $29,267 | $29,267 | $29,267 | $30,053 |
| Amortization Of Intangibles | $29,267 | $29,267 | $29,267 | $30,053 |
| Depreciation | $324,517 | $355,807 | $322,816 | $247,199 |
| Gain Loss On Sale Of PPE | $2,093 | $6,784 | $3,939 | $5,170 |
| Net Income From Continuing Operations | $-56,024,898 | $-61,036,608 | $-53,471,622 | $-50,513,568 |
| Change In Receivables | - | $0 | $12,417 | $233,623 |
| Changes In Account Receivables | - | $0 | $12,417 | $233,623 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
Fetched: 2026-06-23